A biotech executive with broad experience in global regulatory strategic planning and interactions, partnering transactions with large-pharma companies, public company roadshows and financing. Dr Hart brings extensive experience in managing critical global programs ranging from preclinical work through Phase 3 clinical trials.
Prior to SpliSense, Dr. Hart served as CEO of Mitoconix Bio (2017-2019). She also served as General Manager of OPKO Biologics (2014 – 2017) and as VP of Pre-clinical and Clinical Pharmacology at PROLOR Biotech in 2009 -2013, following her role as a Senior Director at the company.
In 2005-2007, Dr. Hart was a Research Fellow at Yale University’s School of Medicine. She received Cum Laude PhD and MSc degrees from the Weizmann institute of Science and graduated Summa Cum Laude from the Technion with a Biotechnology Engineering degree.
Dr. Hart published numerous papers and patents. Her scientific work focused on autoimmunity diseases as well as on B and T cell maturation and migration that can directly affect inflammation and immune conditions.